|
A phase I study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma. |
|
|
Consulting or Advisory Role - Array BioPharma; Regeneron; Sun Pharma |
Research Funding - Novartis (Inst) |
|
|
Employment - Texas Oncology; US Oncology |
|
|
Research Funding - Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst) |
|
|
Employment - Senhwa Biosciences |
Leadership - Senhwa Biosciences; Senhwa Biosciences |
Stock and Other Ownership Interests - Senhwa Biosciences |
Patents, Royalties, Other Intellectual Property - I hold multiple patents relating to the small molecules CX-4945 and CX-5461 |
Travel, Accommodations, Expenses - Senhwa Biosciences |
|
|
Employment - Senhwa Biosciences |
|
|
Research Funding - Senhwa Biosciences |
|
|
Employment - Senhwa Biosciences |
Travel, Accommodations, Expenses - Senhwa Biosciences |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Novartis; Sanofi; Sun Biopharma |
|
|
Research Funding - Senhwa Biosciences |